PRRT2 and cardiac hypertrophy: Activation of PKC in diabetic cardiomyopathy and cardiac hypertrophy reveals that different PKC inhibitors may prevent these diseases as some of these agents have been found effective in attenuating abnormal cardiomyocyte function [118,127].